Mylan said it recently launched a generic version of Warner Chilcott’s oral contraceptive Loestrin 24 Fe in the U.S., following final FDA approval.

The launch comes as brandmaker Actavis, which purchased Warner Chilcott last year, continues to fight generic challenges to other versions of the birth control pill.

Loestrin 24 Fe (norethindrone acetate and ethinyl estradiol tablets USP, 1 mg/0.02 mg and ferrous fumarate) had U.S. sales of roughly $24.4 million for the 12 months ending Sept. 30, 2014, Mylan said, referring to IMS Health figures. — Jonathon Shacat

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.